Restatement of Previously Issued Financial Statements - Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (14,439)	$ (127,792)	$ (23,522)	$ 2,882	$ (18,830)	$ (31,187)	$ (142,231)	$ (50,017)	$ (157,366)	$ (47,135)	$ (295,547)	$ (70,657)	$ (111,367)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		2,439				1,986	5,346	3,965	8,740	5,936	11,873	7,901	7,758
Amortization of debt issuance costs and discount		3,336				3,028	6,743	6,160	10,259	9,393	13,428	12,695	11,958
Equity-based compensation expense		5,157				3,805	10,906	7,799	16,074	12,592	21,127	18,671	10,865
Goodwill impairment	0	85,000	0	0	0	0	85,000	0	85,000	0	85,000	0	53,544
Impairment of right-of-use assets											0	0	901
Non-cash lease expense		94				(35)	363	297	553	450	720	597	174
Provision for doubtful accounts		171				882	176	1,557	220	1,607	228	1,739	55
Deferred income tax benefit		(23)				54	(37)	53	(37)	53	(328)	(235)	(1,924)
Net increase (decrease) in fair value of derivatives		23,807				13,012	15,726	15,442	14,396	(1,827)	107,658	7,361	(21,387)
Loss on sale of property and equipment						8		8		10	0	10	0
Changes in assets and liabilities:
(Increase) decrease in accounts receivable		(8,957)				(3,469)	(6,232)	(7,735)	(5,396)	(546)	(11,753)	6,403	(798)
Decrease (increase) in contract assets		2,443				(1,115)	3,781	966	3,078	860	3,927	(3,510)	(286)
Decrease (increase) in prepaid expenses and other assets		950				1,488	1,243	5,244	1,540	6,181	2,076	5,899	(1,702)
(Decrease) increase in accounts payable		(5,960)				(4,914)	(5,047)	(8,124)	(8,224)	(6,346)	(4,027)	(4,384)	9,942
(Decrease) increase in accrued liabilities		2,599				4,066	1,652	660	7,610	2,035	(2,873)	2,637	(5,121)
Increase (decrease) in contract liabilities		1,826				325	1,469	(22)	486	298	514	(1,143)	(3,740)
(Decrease) increase in other liabilities		551				49	(275)	(1,066)	(246)	(1,794)	(1,414)	(2,291)	2,210
Net cash used in operating activities		(14,359)				(12,017)	(21,417)	(24,813)	(23,313)	(18,233)	(38,119)	(18,307)	(48,918)
Cash flows from investing activities:
Acquisition of business, net of cash acquired		13,935					13,935		13,935		13,935	0	(4,465)
Purchases of property and equipment		(38)				0	(167)	(2)	(304)	(2)	(484)	(2)	(769)
Capitalized software development costs		(1,643)				0	(3,225)	0	(7,396)	(2,744)	(10,630)	(3,828)	0
Net cash provided by (used in) investing activities		12,254				0	10,543	(2)	6,235	(2,746)	2,821	(3,830)	(5,234)
Cash flows from financing activities:
Proceeds from issuance of Private Placement and Registered Direct Offering shares						25,000		50,000		50,000	0	50,000	0
Payment of Private Placement and Registered Direct Offering transaction costs						(3,025)		(5,225)		(5,724)	0	(5,724)	0
Repurchase of shares as a result of forward share purchase agreements											0	0	(100,896)
Proceeds from short-term borrowings											817	1,229	2,059
Repayment of short-term borrowings		(403)				(763)	(812)	(1,537)	(1,229)	(2,059)	(1,229)	(2,059)	(4,233)
Issuance of common stock upon ESPP purchase		0				0	607	0	607	531	1,367	1,176	0
Payments of tax withholding from the issuance of common stock		(2,532)				0	(3,140)	(1,132)	(3,143)	(2,217)	(2,378)	(2,560)	(67)
Net cash provided by (used in) financing activities		50,960				21,212	50,583	42,106	50,163	40,531	52,458	42,062	(103,137)
Net increase (decrease) in cash and cash equivalents		48,855				9,195	39,709	17,291	33,027	19,552	17,584	19,925	(157,289)
Cash and cash equivalents at the beginning of period	81,412	32,557	32,184	29,923	21,827	12,632	32,557	12,632	32,557	12,632	32,557	12,632	169,921
Cash and cash equivalents at the end of the period	72,266	81,412	32,557	32,184	29,923	21,827	72,266	29,923	65,584	32,184	50,141	32,557	12,632
As previously reported
Cash flows from operating activities:
Net loss	(11,737)	(125,147)	(21,256)	3,999	(16,895)	(26,214)	(136,884)	(43,109)	(149,060)	(39,110)		(60,366)	(121,674)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		2,439				1,986	5,346	3,965	8,740	5,936		7,901	7,758
Amortization of debt issuance costs and discount		506				500	1,012	1,006	1,517	1,512		2,018	2,302
Equity-based compensation expense		5,157				3,805	10,906	7,799	16,074	12,592		18,671	10,865
Goodwill impairment	0	85,000	0	0	0	0	85,000	0	85,000	0		0	53,544
Impairment of right-of-use assets												0	901
Non-cash lease expense		94				(35)	363	297	553	450		597	174
Provision for doubtful accounts		171				882	176	1,557	220	1,607		1,739	55
Deferred income tax benefit		(23)				54	(37)	53	(37)	53		88	(1,757)
Net increase (decrease) in fair value of derivatives		23,992				10,567	16,110	13,688	14,832	(1,971)		7,424	(1,591)
Loss on sale of property and equipment						8		8		10		10	0
Changes in assets and liabilities:
(Increase) decrease in accounts receivable		(8,957)				(3,469)	(6,232)	(7,735)	(5,396)	(546)		6,403	(798)
Decrease (increase) in contract assets		2,443				(1,115)	3,781	966	3,078	860		(3,510)	(286)
Decrease (increase) in prepaid expenses and other assets		950				1,488	1,243	5,244	1,540	6,181		5,899	(1,702)
(Decrease) increase in accounts payable		(5,960)				(4,914)	(5,047)	(8,124)	(8,224)	(6,346)		(4,384)	9,942
(Decrease) increase in accrued liabilities		2,599				4,066	1,652	660	7,610	2,035		2,637	(5,121)
Increase (decrease) in contract liabilities		1,826				325	1,469	(22)	486	298		(1,143)	(3,740)
(Decrease) increase in other liabilities		551				49	(275)	(1,066)	(246)	(1,794)		(2,291)	2,210
Net cash used in operating activities		(14,359)				(12,017)	(21,417)	(24,813)	(23,313)	(18,233)		(18,307)	(48,918)
Cash flows from investing activities:
Acquisition of business, net of cash acquired		13,935					13,935		13,935			0	(4,465)
Purchases of property and equipment		(38)				0	(167)	(2)	(304)	(2)		(2)	(769)
Capitalized software development costs		(1,643)				0	(3,225)	0	(7,396)	(2,744)		(3,828)	0
Net cash provided by (used in) investing activities		12,254				0	10,543	(2)	6,235	(2,746)		(3,830)	(5,234)
Cash flows from financing activities:
Proceeds from issuance of Private Placement and Registered Direct Offering shares						25,000		50,000		50,000		50,000	0
Payment of Private Placement and Registered Direct Offering transaction costs						(3,025)		(5,225)		(5,724)		(5,724)	0
Repurchase of shares as a result of forward share purchase agreements												0	(100,896)
Proceeds from short-term borrowings												1,229	2,059
Repayment of short-term borrowings		(403)				(763)	(812)	(1,537)	(1,229)	(2,059)		(2,059)	(4,233)
Issuance of common stock upon ESPP purchase		0				0	607	0	607	531		1,176	0
Payments of tax withholding from the issuance of common stock		(2,532)				0	(3,140)	(1,132)	(3,143)	(2,217)		(2,560)	(67)
Net cash provided by (used in) financing activities		50,960				21,212	50,583	42,106	50,163	40,531		42,062	(103,137)
Net increase (decrease) in cash and cash equivalents		48,855				9,195	39,709	17,291	33,027	19,552		19,925	(157,289)
Cash and cash equivalents at the beginning of period	81,412	32,557	32,184	29,923	21,827	12,632	32,557	12,632	32,557	12,632	32,557	12,632	169,921
Cash and cash equivalents at the end of the period	72,266	81,412	32,557	32,184	29,923	21,827	72,266	29,923	65,584	32,184		32,557	12,632
Restatement adjustment
Cash flows from operating activities:
Net loss	(2,702)	(2,645)	(2,266)	(1,117)	(1,935)	(4,973)	(5,347)	(6,908)	(8,306)	(8,025)		(10,291)	10,307
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		0				0	0	0	0	0		0	0
Amortization of debt issuance costs and discount		2,830				2,528	5,731	5,154	8,742	7,881		10,677	9,656
Equity-based compensation expense		0				0	0	0	0	0		0	0
Goodwill impairment	0	0	0	0	0	0	0	0	0	0		0	0
Impairment of right-of-use assets												0	0
Non-cash lease expense		0				0	0	0	0	0		0	0
Provision for doubtful accounts		0				0	0	0	0	0		0	0
Deferred income tax benefit		0				0	0	0	0	0		(323)	(167)
Net increase (decrease) in fair value of derivatives		(185)				2,445	(384)	1,754	(436)	144		(63)	(19,796)
Loss on sale of property and equipment						0		0		0		0	0
Changes in assets and liabilities:
(Increase) decrease in accounts receivable		0				0	0	0	0	0		0	0
Decrease (increase) in contract assets		0				0	0	0	0	0		0	0
Decrease (increase) in prepaid expenses and other assets		0				0	0	0	0	0		0	0
(Decrease) increase in accounts payable		0				0	0	0	0	0		0	0
(Decrease) increase in accrued liabilities		0				0	0	0	0	0		0	0
Increase (decrease) in contract liabilities		0				0	0	0	0	0		0	0
(Decrease) increase in other liabilities		0				0	0	0	0	0		0	0
Net cash used in operating activities		0				0	0	0	0	0		0	0
Cash flows from investing activities:
Acquisition of business, net of cash acquired		0					0		0			0	0
Purchases of property and equipment		0				0	0	0	0	0		0	0
Capitalized software development costs		0				0	0	0	0	0		0	0
Net cash provided by (used in) investing activities		0				0	0	0	0	0		0	0
Cash flows from financing activities:
Proceeds from issuance of Private Placement and Registered Direct Offering shares						0		0		0		0	0
Payment of Private Placement and Registered Direct Offering transaction costs						0		0		0		0	0
Repurchase of shares as a result of forward share purchase agreements												0	0
Proceeds from short-term borrowings												0	0
Repayment of short-term borrowings		0				0	0	0	0	0		0	0
Issuance of common stock upon ESPP purchase		0				0	0	0	0	0		0	0
Payments of tax withholding from the issuance of common stock		0				0	0	0	0	0		0	0
Net cash provided by (used in) financing activities		0				0	0	0	0	0		0	0
Net increase (decrease) in cash and cash equivalents		0				0	0	0	0	0		0	0
Cash and cash equivalents at the beginning of period	0	0	0	0	0	0	0	0	0	0	$ 0	0	0
Cash and cash equivalents at the end of the period	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0		$ 0	$ 0